quote:Originally posted by ski3272: Whats everyones thoughts on this one up down I dont understand why this share didnt go up today after all the news and tv show.
This is a very big part of it.
quote:Originally posted by BooDog: · The Conversion Price set forth in each outstanding 2005 debenture, 2006 debenture, and 2007 debenture held by Prior Purchasers who participated in the 2008 Financing was reset to $0.15;
· The Exercise Price set forth in each outstanding 2005 warrant, 2006 warrant, and 2007 warrant held by Prior Purchasers who participated in the 2008 Financing was reset to $0.165; and
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
When is the R/S happening? The board approved it to be executed mid April, correct?
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
posted
R/S means reverse split. It typically is bad, especially in the Pinks, or BB. This company is the new IBM in there field, but without government funding, they have to raise capital. The only real way is dilution.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
posted
The next congress will most assuredly approve stem cell funding. I would get in this after the split and after the initial drop after the split.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
quote:Originally posted by invester: When is the R/S happening? The board approved it to be executed mid April, correct?
Not sure, But the way these convertibles were changed I wouldn't put it past them to also change the value from 1:2 - 1:10 to something like 1:100.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
No doubt IMAKE. I thought today would be that play, my guess is the insiders knew what I was thinking (and many others). Out for now but I'm watching.
Cheers M8.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
wow the good news sure stopped fast lol I wish the bad news was posted first i wouldnt have baught a bunch of shares at 13. is there any chance it hits 13 again before the split?
-------------------- "The Stock Market Roller Coaster is my favorite ride at the park" Posts: 211 | From: MN | Registered: Mar 2008
| IP: Logged |
Our system posted a WAIT today. The previous SELL recommendation was issued on 04.01.2008 (1) day ago, when the stock price was 0.1600. Since then ACTC has fallen -36.25% .
Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays.
-------------------- "The Stock Market Roller Coaster is my favorite ride at the park" Posts: 211 | From: MN | Registered: Mar 2008
| IP: Logged |
quote:Originally posted by ski3272: ADVANCED CELL TECHNOLOGY INC Daily Commentary
Our system posted a WAIT today. The previous SELL recommendation was issued on 04.01.2008 (1) day ago, when the stock price was 0.1600. Since then ACTC has fallen -36.25% .
Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays.
Don't buy or sell on another individuals Short or Long signals. I am a seasoned trader, and if you just read the 10k it will clearly tell you that there is a Reverse Split coming before the end of April. Any knowledgeable trader should know that they pumped the Barbra W. interview to unleash some funding "stock". Just be cautious if you are a newbie as the R/S is coming and your account will get hurt. As a season trader, I tell you to wait for the R/S, then the drop after, then buy when it hits the bottom. I feel they are fully funded till congress passes approval on stem cells. This truly will be the IBM of the stem cell market. IMHO.
Posts: 4381 | From: houston | Registered: Mar 2006
| IP: Logged |
quote:Originally posted by ski3272: I baught in at 13 thinking this sucker would go but oh no poof crash bang boom. Im ready to go back to playing black jack the odds were better.
Did you buy on the gap today???
Posts: 2383 | Registered: Apr 2006
| IP: Logged |
quote:Originally posted by ski3272: i baught right away at the open thinking it waS going up right away. do you think it will hit the 13 again ? soon
There is a chance. Dam crazy 8 ball quit working for me yesterday! Couple factors, first - we know about the convertibles and their price so there is a major resistance level there. Second there is a major seller on top of this right now that obviously doesn't give a crap about the pps. The only thing that stopped this from crashing major yest is people realized they were up to the same tricks they were pulling the last time we thought they had real good news so people quit loading up looking for the bounce. Still had decent buys all through yest but the seller was just too much. Check the filings and you'll see the deal Advance cut. When he's out then this will have a chance imo - at least until it gets back to the conversion price.
Anyway - just my WAG.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Platform Yields Over 140 Cell Types from Human Embryonic Stem Cells Thursday April 3, 8:30 am ET Research Represents a Breakthrough in the Mapping and Characterization of the Cells of Early Human Development; Company to provide differentiated embryonic progenitor cell lines from its ACTCellerate Platform for therapeutic applications, research tools, and drug discovery
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC; www.advancedcell.com) reported today on a large-scale differentiation process that has generated panels of differentiating human progenitor cell lines from human embryonic stem cells (hESCs). The research will be published in the April issue of Regenerative Medicine (Vol. 3[3] e-pub ahead of print) and will be freely available at www.futuremedicine.com/loi/rme. ADVERTISEMENT
Since the first isolation of hESCs, scientists and industry alike have been working to harness the power of these cells for the purpose of restoring and regenerating body systems that have been damaged by disease or injury
One of the hurdles has been a commercially viable means for the expansion of sufficient numbers of the cell types needed for tissue regeneration. With the publication of work entitled “The ACTCellerate Initiative: large-scale combinatorial cloning of novel human embryonic stem cell derivatives,” ACT scientists have solved some of these problems. The paper describes a system that was established to isolate and clonally expand tissue specific precursors that heretofore could only be isolated from aborted human fetal tissue.
Dr Chris Mason (UCL), Associate Editor of Regenerative Medicine said, “This is an enormously exciting development for the regen sector. The research reported… represents a quantum leap forward in embryonics, the mapping and characterization of the cells of early human development. Without any doubt, the ACTCellerate technology will greatly hasten the translation of human embryonic stem cell-based therapies into safe and effective products for routine clinical practice.”
The benefits of the ACTCellerate technology transcend therapeutics and extend as well into revolutionary applications for drug discovery, drug toxicity testing, and cancer research. This advance holds great promise for future research and may one day lead to many new cell-based therapies in the emerging field of regenerative medicine.
Another important finding in this publication is that these normal embryonic progenitor cell types show the expression of certain genes (such as oncofetal markers) often associated in the literature with malignant cancer. However, when these progenitor cells were injected into supportive mice, no malignant tumors could be observed. This indicates that expression of such genes is a function of these cells’ normal primitive stage of differentiation and not linked to any disease potential.
William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc., stated, “We are greatly indebted to Mike West for his insight in initiating this program during his tenure with ACT and to the entire ACT scientific team for their perseverance in bringing this groundbreaking research to the conclusions described in this publication. ACT has taken great strides in identifying both clinical applications for this approach as well as for the ACTCellerate cell line library for drug target discovery, assay development, and direct therapeutics development across a wide spectrum of clinical indications. We are now in a position to offer our refined technology and know-how to potential partners and licensees.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
posted
Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies
Apr 10, 2008 09:18:01 (ET)
ALAMEDA, Calif., Apr 10, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Jonathan H. Dinsmore Ph.D., Senior Vice President - Regulatory and Clinical, has been invited to present to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Advisory Committee on Cellular, Tissue and Gene Therapies. Dr. Dinsmore will deliver a presentation today titled, "Safety Considerations for the Clinical Application of Human Embryonic Stem Cells" to the FDA panel, which will convene at the Hilton Hotel in Gaithersburg, Maryland. The presentation is scheduled for 10 a.m. eastern time. The panel is expected to conduct hearings on Cellular Therapies Derived from Human Embryonic Stem Cells Scientific Considerations for Pre-Clinical Safety Testing. Other companies invited to present include Geron Corporation (GERN, Trade ) and Novocell, Inc.
During Dr. Dinsmore's presentation, he is expected to discuss cell sourcing, manufacturing and delivery of human embryonic stem cells. He will also present certain conclusions from pre-clinical activities surrounding the company's retinal pigmented epithelial (RPE) cell therapy. Advanced Cell recently completed discussions with the FDA regarding this program through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials. The entire presentation will be available on the company's web site at http://www.advancedcell.com/conference-presentations after 11 a.m. eastern time today.
"We are honored that the FDA has invited us to participate in this panel, which could be influential in shaping the clinical pathway for the testing of embryonic stem cells," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "As one of the few stem cell companies that is preparing for later-stage clinical trials, we are pleased that we will be able to share our views with FDA executives and other distinguished members of the scientific community on the safety issues surrounding human embryonic stem cell development."
Additional details on the FDA meeting may be found at http://www.fda.gov/ohrms/dockets/ac/cber08.html#CellularTissueGene Therapies (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
CEOcast, Inc. for Advanced Cell Technology Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
quote:Originally posted by Bottomfeeder: Which is the correct symbol...ACTC or ACTCE?
ACTCE
ACTC
lol
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[BadOne]](graemlins/headbash.gif)
![[Were Up]](graemlins/wereup.gif)
![[Big Grin]](biggrin.gif)
![[Good Luck]](graemlins/goodluck.gif)
